Robeco Institutional Asset Management B.V. Lowers Holdings in Abbott Laboratories $ABT

Robeco Institutional Asset Management B.V. lowered its holdings in shares of Abbott Laboratories (NYSE:ABT - Free Report) by 31.7% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 280,285 shares of the healthcare product maker's stock after selling 130,318 shares during the quarter. Robeco Institutional Asset Management B.V.'s holdings in Abbott Laboratories were worth $38,122,000 at the end of the most recent reporting period.

A number of other large investors also recently added to or reduced their stakes in ABT. Woodward Diversified Capital LLC boosted its position in shares of Abbott Laboratories by 30.5% during the second quarter. Woodward Diversified Capital LLC now owns 6,056 shares of the healthcare product maker's stock worth $824,000 after acquiring an additional 1,417 shares during the last quarter. Community Financial Services Group LLC lifted its stake in Abbott Laboratories by 874.7% in the 2nd quarter. Community Financial Services Group LLC now owns 45,110 shares of the healthcare product maker's stock worth $6,135,000 after purchasing an additional 40,482 shares in the last quarter. Madrona Financial Services LLC boosted its holdings in shares of Abbott Laboratories by 9.7% during the 2nd quarter. Madrona Financial Services LLC now owns 1,726 shares of the healthcare product maker's stock valued at $235,000 after purchasing an additional 152 shares during the last quarter. SOA Wealth Advisors LLC. grew its position in shares of Abbott Laboratories by 142.5% during the second quarter. SOA Wealth Advisors LLC. now owns 1,113 shares of the healthcare product maker's stock valued at $151,000 after purchasing an additional 654 shares in the last quarter. Finally, Parkwoods Wealth Partners LLC bought a new stake in shares of Abbott Laboratories in the second quarter worth about $208,000. 75.18% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research firms have weighed in on ABT. Weiss Ratings restated a "buy (b)" rating on shares of Abbott Laboratories in a report on Saturday, September 27th. BTIG Research reduced their price target on shares of Abbott Laboratories from $148.00 to $145.00 and set a "buy" rating on the stock in a research report on Friday, July 18th. Royal Bank Of Canada upped their price target on shares of Abbott Laboratories from $145.00 to $147.00 and gave the company an "outperform" rating in a research note on Tuesday, July 15th. Leerink Partnrs raised shares of Abbott Laboratories to a "hold" rating in a research note on Monday, June 16th. Finally, Mizuho upped their target price on shares of Abbott Laboratories from $130.00 to $140.00 and gave the company a "neutral" rating in a research report on Wednesday, July 16th. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and four have issued a Hold rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $145.39.

Insider Buying and Selling

In related news, CFO Philip P. Boudreau sold 5,550 shares of Abbott Laboratories stock in a transaction dated Friday, August 8th. The shares were sold at an average price of $134.55, for a total transaction of $746,752.50. Following the completion of the sale, the chief financial officer owned 51,003 shares in the company, valued at $6,862,453.65. This trade represents a 9.81% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 0.46% of the stock is owned by corporate insiders.

Abbott Laboratories Stock Performance

Abbott Laboratories stock opened at $134.49 on Friday. The company has a debt-to-equity ratio of 0.25, a current ratio of 1.82 and a quick ratio of 1.30. The firm has a market capitalization of $234.07 billion, a P/E ratio of 16.85, a price-to-earnings-growth ratio of 2.52 and a beta of 0.69. Abbott Laboratories has a 1-year low of $110.86 and a 1-year high of $141.23. The company's 50-day moving average is $131.94 and its 200 day moving average is $131.33.

Abbott Laboratories (NYSE:ABT - Get Free Report) last released its earnings results on Thursday, July 17th. The healthcare product maker reported $1.26 EPS for the quarter, meeting analysts' consensus estimates of $1.26. Abbott Laboratories had a return on equity of 18.32% and a net margin of 32.43%.The firm had revenue of $11.14 billion for the quarter, compared to analysts' expectations of $11.01 billion. During the same quarter in the prior year, the firm posted $1.14 earnings per share. The company's quarterly revenue was up 7.4% on a year-over-year basis. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. Research analysts forecast that Abbott Laboratories will post 5.14 EPS for the current year.

Abbott Laboratories Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, November 17th. Stockholders of record on Wednesday, October 15th will be paid a dividend of $0.59 per share. This represents a $2.36 dividend on an annualized basis and a dividend yield of 1.8%. The ex-dividend date of this dividend is Wednesday, October 15th. Abbott Laboratories's payout ratio is currently 29.57%.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.